Novel Bio

Coming – July 30

Revolutionizing The $6B DNA Manufacturing Industry

Date and Time

July 30

12:00 PM ET 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Novel Bio is an innovator that’s poised to disrupt the $6B plasmid DNA manufacturing industry.

They are replacing 50-year-old DNA production technology with their proven and proprietary NBx Platform. It drastically improves speed, yield, cost, and quality in plasmid DNA manufacturing. As proof, they were able to manufacture a specific strain of DNA in two days for the NIH, which the organization was unable to create it in 6 months using current methods.

Novel Bio has multiple revenue streams: As a CDMO they are delivering DNA on demand for more than 10 clients with a 100% retention rate. They also sell their NBx CyClone Cell Line to over 25 clients including leading healthcare organizations like NIH, Regeneron, AstraZeneca and others. NBx Cyclone offers a drop-in replacement for the current workflows, delivering up to 10x more plasmids with superior DNA quality. Best of all, it doesn’t require new equipment or retraining for lab staff.

Novel Bio has achieved over 200% revenue growth YoY. They have a term sheet in hand for a royalty-plus deal with a top-tier pharmaceutical company. They are currently preparing to launch high margin clinical-grade services and enter new product verticals.

With a backlog of customers and revenue constrained by capacity, Novel Bio is ready to scale quickly. The company is preparing to expand manufacturing and grow their business development team over the next 12 months.

Register today to join our webinar with Novel Bio Co-Founder and CEO, Pankaj Khanna, to hear how the company is projecting break-even by FY2026 using conservative revenue estimates.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.